FindTrial
Sign In

Risk factors for the development and severity of interstitial lung disease associated with EGFR tyrosine kinase inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

Risk factors for the development and severity of interstitial lung disease associated with EGFR tyrosine kinase inhibitors in non-small cell lung cancer: a systematic review and meta-analysis - Risk factors for the development and severity of interstitial lung disease associated with EGFR tyrosine kinase inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050523
Enrollment
Unknown
Registered
2023-03-13
Start date
2023-03-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR tyrosine kinase inhibitor-associated interstitial lung disease

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: This systematic review will target participants as follows: Adult patients with histopathologically diagnosed non-small cell lung cancer with an EGFR mutation who have developed EGFR tyrosine kinase inhibitor-associated interstitial lung disease. EGFR tyrosine kinase inhibitor-associated interstitial lung disease is defined as any lung injury that occurred while using an EGFR tyrosine kinase inhibitor that the clinician judged overall to be drug-related. EGFR tyrosine kinase inhibitors include gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib.

Exclusion criteria

Exclusion criteria: Pediatric patients under 18 years of age Adult patients with histopathologically diagnosed small-cell lung cancer

Design outcomes

Primary

MeasureTime frame
Risk factors for the severity of interstitial lung disease—

Secondary

MeasureTime frame
Risk factors for the development of interstitial lung disease—

Countries

Japan

Contacts

Public ContactYosuke Fukuda

Showa University, School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology

y.f.0423@med.showa-u.ac.jp+81-3-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026